Hydrofluoroalkane beclomethasone dipropionate extra fine aerosol efficacy response at reduced dose compared to other inhaled corticosteroid treatment regimens Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
Nebulized beclomethasone dipropionate is as effective and as well tolerated than nebulized budesonide to prevent asthma exacerbations in infants Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001
Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001
Real-life effectiveness of beclomethasone diproprionate/formoterol extra-fine combination in adult patients with persistent asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011
Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002
Salmeterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Inhalation of beclomethason dipropionate spray compared with theophilline as primary treatment for chronic mild-to-moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002
A pharmaco-epidemiological audit of beclomethasone dipropionate extrafine aerosol in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 471s Year: 2002
The clinical effectiveness of HFA-beclomethasone dipropionate in children with moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 166s Year: 2004
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Long-term benefits of switching to hydrofluoroalkane beclomethasone dipropionate extrafine aerosol Source: Eur Respir J 2001; 18: Suppl. 33, 331s Year: 2001
Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
Assessment of long-term effects of combined extra-fine beclomethasone and formoterol treatment in asthma patients using functional imaging Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007
Efficacy, safety and cost of using beclomethason dipropionate in patients with persistent moderate bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004
Aerosolized bechlometasone dipropionate (BDP) delivered via TNI® vesicles: a new approach for the treatment of asthmatic and COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 501s Year: 2002
HFA vs CFC beclomethasone dipropionate – comparative effectiveness in asthma management Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001